If you're a biotech trader or investor, you know who Adam Feuerstein is. The senior reporter for TheStreet, Inc. TST is known across the biotech industry for his straight-shooting analysis, ability to cut through corporate jargon, and in-depth reporting on drug companies. Plus, there's his provacative Twitter feed.
On Friday, March 10 at 9 a.m. ET, Feuerstein will join Benzinga's PreMarket Prep show to discuss the impact President Donald Trump could have on the industry, which biotech stocks are most vulnerable to pricing legislation, and his thoughts on the Novo Nordisk A/S NVO—Global Blood Therapeutics Inc GBT rumors.
Have a question you want to ask? Create a free account and join our live chat before and during the interview. If you miss it live, you can also listen to the podcast after it's posted on Soundcloud.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
